A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07767903
This study is recruiting at 11 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day [mg/day]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Generalized Anxiety Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Last updated on ClinicalTrials.gov
- October 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Anderson Clinical Research · Redlands, CA
Florida · 1
- Clinical Neuroscience Solutions Inc. (CNS) - Orlando · Orlando, FL
Massachusetts · 1
- Adams Clinical - Watertown · Watertown, MA
New Jersey · 1
- Lumina Clinical Research Center · Cherry Hill, NJ
New York · 2
- Basil Clinical · Jamaica, NY
- IMA Clinical Research NYC Uptown · New York, NY
Oregon · 1
- Summit Research Network · Portland, OR
Pennsylvania · 1
- Adams Clinical Philadelphia · Philadelphia, PA
Tennessee · 1
- CNS Healthcare - Memphis · Memphis, TN
Texas · 1
- DM Clinical Research - Bellaire · Houston, TX
Washington · 1
- Core Clinical Research · Everett, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.